Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Post TAVR Aspirin vs. Clopidogrel: Conflicting Findings and Guidelines

One month ago we shared a meta-analysis stating aspirin (ASA) as the best antiplatelet following TAVR vs. 3 to 6 dual antiplatelet therapy suggested by guidelines.  At that time, guideline recommendations appeared obsolete. Several studies had started to support ASA monotherapy as the best antiaggregation scheme after TAVR. However, in the light of this new<a href="https://solaci.org/en/2021/06/04/post-tavr-aspirin-vs-clopidogrel-conflicting-findings-and-guidelines/" title="Read more" >...</a>

EuroPCR 2021 | TVT Registry: Outcomes of TAVR in Low Surgical Risk Bicuspids

In bicuspid patients with aortic stenosis and low surgical risk, transcatheter aortic valve replacement (TAVR) with balloon expandable valve offers results comparable to normal anatomy results.  These data come from the TVT registry, presented at EuroPCR 2021 scientific sessions. Stroke and death rates (inhospital, 30 days and one year) in bicuspid patients did not result<a href="https://solaci.org/en/2021/05/27/europcr-2021-tvt-registry-outcomes-of-tavr-in-low-surgical-risk-bicuspids/" title="Read more" >...</a>

EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development

According to this recent meta-analysis of randomized studies, ultrathin strut devices are associated with lower rates of target vessel failure vs. 2nd generation drug eluting stents (DES). This advantage was driven by fewer clinically justified reinterventions.  This study was published in the European Heart Journal and simultaneously presented at EuroPCR 2021 Scientific Sessions. Ultrathin struts<a href="https://solaci.org/en/2021/05/26/europcr-2021-ultrathin-struts-consolidate-as-next-des-development/" title="Read more" >...</a>

EuroPCR 2021 | FUTURE II: las plataformas bioabsorbibles vuelven recargadas

EuroPCR 2021 | FUTURE II: Bioresorbable Scaffolds Reloaded

A new sirolimus-eluting bioresorbable scaffold with far thinner struts resulted non inferior to the Xience as to the end point of angiographic in-segment late loss (LL) powered for noninferiority testing. Even though this is a small study with angiographic end points, it might be the first step towards the return of bioresorbable scaffolds.  Read also:<a href="https://solaci.org/en/2021/05/26/europcr-2021-future-ii-bioresorbable-scaffolds-reloaded/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet thrombosis compared with the standard of care. These data come from the computerized tomography (CT) scan sub-study from ATLANTIS, presented during the scientific sessions of the American College of Cardiology (ACC) 2021 Congress. In patients with no prior<a href="https://solaci.org/en/2021/05/19/acc-2021-atlantis-4d-ct-apixaban-and-sub-clinical-thrombosis-after-tavr/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard antithrombotic treatment, according to the randomized ATLANTIS trial presented today at the American College of Cardiology (ACC) 2021 Congress. Given its easy indication and good safety profile, it could be an option to vitamin K antagonists for patients with<a href="https://solaci.org/en/2021/05/18/acc-2021-atlantis-apixaban-after-tavr-vs-standard-of-care/" title="Read more" >...</a>

Is Rheumatic Etiology Counter Indicated for TAVR?

Patients with rheumatic aortic stenosis have been systematically excluded from all studies on transcatheter aortic valve replacement (TAVR).  This study compared TAVR vs surgical aortic valve replacement (SAVR) outcomes in patients with rheumatic aortic stenosis and also vs TAVR outcomes in patients with degenerative aortic stenosis.  The study looked at rheumatic aortic stenosis patients receiving<a href="https://solaci.org/en/2021/05/17/is-rheumatic-etiology-counter-indicated-for-tavr/" title="Read more" >...</a>

Validating Consensus on Post TAVR Conduction Disturbances in the Clinical Practice

Little over a year ago, JACC published the expert consensus on the management of post transcatheter aortic valve replacement (TAVR) conduction disturbances. This publication homogenized criteria and was welcomed by operators who, when in doubt, tended to prematurely indicate definite pacemaker implantation or delayed discharge in order to monitor patients.  These criteria, however, was nothing<a href="https://solaci.org/en/2021/05/12/validating-consensus-on-post-tavr-conduction-disturbances-in-the-clinical-practice/" title="Read more" >...</a>

El aumento de la experiencia de los operadores mejora los resultados en el TAVI

ST-Segment Elevation Infarction After TAVR: Problems in Every Aspect

For interventional cardiologists, treating an ST-segment elevation infarction in a patient with transcatheter aortic valve replacement (TAVR) is challenging in many ways. Longer door-to-balloon times and higher rates of primary angioplasty failure than in the general population are translated into very high short- and mid-term mortality. This multicenter study, recently published in JACC, included 118 patients<a href="https://solaci.org/en/2021/05/10/st-segment-elevation-infarction-after-tavr-problems-in-every-aspect/" title="Read more" >...</a>

Most read scientific articles of april at solaci.org

The most read scientific articles on interventional cardiology of april

01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.  Read more HERE 02- Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports This is one of the<a href="https://solaci.org/en/2021/05/07/the-most-read-scientific-articles-on-interventional-cardiology-of-april/" title="Read more" >...</a>